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INTRODUCTION:   
The present investigation deals with the formulation, 
optimization and evaluation of sodium alginate based 
floating oral In situ gel of Ranitidine Hydrochloride. 
Sodium alginate used as a polymer and CaCO3 was used as 
a cross- 3 linking agent. Oral administration is most 
convenient and preferred means of any drug delivery to the 
systemic circulation. Oral sustained release drug delivery 
recently have been increasing interest in pharmaceutical 
field to achieve improved therapeutic advantages, such as 
ease of dosing administration, patient compliance and 
flexibility in formulation. In-situ forming polymeric 
formulations drug delivery systems is in solution form 
before administration in the body, but once administered, 
undergoes gelation in-situ to form a gel. The formulation 
of gel depends upon factors like temperature modulation, 
pH changes, presence of ions and ultraviolet irradiation, 
from which drug gets released in sustained and controlled 
manner. The objective of this study was to develop a novel 
in- situ gel system for sustained drug delivery using natural 
biodegradable polymers. The system utilizes polymers that 
exhibit solution-to-gel phase transition due to change in 
specific physicochemical parameters. In-situ gel was 
formed at a biological pH from designed set of 
experiments, it was evident that formulation containing 2 
% of sodium alginate control the release of drug for longer 
duration. The in-situ gel exhibited the expected, viscosity, 
drug content, pH, in vitro gelling capacity, in vitro floating 
ability and sustained drug release. Ranitidine 
hydrochloride is a H2-antagonist competitively inhibits 
histamine actions at all H2-receptors, but are mainly used 
clinically as inhibitors of gastric acid secretion. Local 
availability of H2-antagonists in stomach has a greater 
clinical significance in treatment of peptic ulcer. 
Ranitidine hydrochloride is a H2 antagonist, is widely 
prescribed in active duodenal ulcers, gastric ulcers and 
gastroesophageal reflux disease. In the present study, an 
attempt was made to develop a gastro-retentive in situ 
gelling liquid formulation using ranitidine for local release 
in the stomach. Gastro-retentive in situ gelling liquid 
formulations were formulated using different grades and 
concentrations of sodium alginate. 
Sustained release forms: The goal of any drug delivery 
system is to provide a therapeutic amount of drug to the 
proper site in the body to achieve promptly, and then 
maintain, the desired drug concentration. That Spatial 
placement relates to targeting a drug to a specific organ or 
tissue, while temporal delivery refers to controlling the rate 
of drug delivery to the target tissue. An approximately 
designed sustained release drug delivery system can be a 
major advance toward sowing these two problems. Most 
sustained-release forms are designed so that the 
administration of a single dosage unit provides the 
immediate release of an amount of drug that promptly 
produces the desired therapeutic effect and gradual and 
continual release of additional amounts of drug to maintain 
this level of effect over an extended period, usually 8 to 
12hrs. In general, the drugs best suited for incorporation 
into a sustained release product have following 
characteristics. 
1. They exhibit neither every slow nor very fast rates of 
absorption and excretion. 
2. They are uniformly absorbed from the gastro intestinal 
tract. 
3. They possess a good margin of safety1. 
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MATERIAL AND METHODS 
Materials 
Ranitidine Hydrochloride (RHCL) Was Received As a Gift 
Sample From Ranbaxy Pharmaceuticals Ltd (India). 
Sodium Alginate (SA) Were Purchased From Loba chemie 
(P) Ltd. Mumbai, Calcium Carbonate, Sodium Citrate, D-
sorbitol, Potassium chloride And Sodium chloride Were 
Purchased From Centeral Drug House (P) Ltd. New delhi 
(India). All Other Chemicals Used In The Study Were of 
Analytical Grade. 
Methods 
Preparation of Ranitidine in situ gelling solution
 – SA 
(sodium alginate) Solution was prepared in distilled water 
by heating to 600C under continuous stirring. After cooling 
below  40 0C.  Ingredients including drug, gelling agent 
and other excipients were weighed accurately on butter 
paper with the help of a stainless steel then Sodium 
alginate solution of difference concentrations (1, 1.5 and 
2gm) were prepared by adding the sodium alginate to 
distilled water containing difference concentration 
(0.25gm, 0.5gm) calcium carbonate, and difference 
concentration (0.25gm, 0.5gm) sodium citrate and heating 
to 600C and after cooling below 400C and continuous 
stirring. Appropriate amounts of Ranitidine hydrochloride 
0.30 (gm) and flavouring agent (the optimized 
concentrations 1, 2, 3 gm of D-sorbitol) were then 
dissolved in the resulting solution and formulation were 
prepared. The resulting formulations were finally stored in 
amber coloured bottles until further use2.
 
Table 1: Composition of Floating in situ gel 
Ingredients          Formulation code & Quantities   
 F1 F2 F3 F4 F5 F6 
Ranitidine Hydrochloride 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg                   
Sodium Alginate 1gm 1.5 gm 2 gm 1 gm 1.5 gm 2 gm 
Sodium Citrate 250 mg 250 mg 250 mg 500 mg 500 mg 500 mg                 
CaCo3 250 mg 250 mg 250 mg 500mg 500mg 500mg 
D. sorbitol 1gm 2gm 3gm 1gm 2gm 3gm 
Distil Water q.s. q.s. q.s. q.s. q.s.  q.s. 
Total weight (ml) 100ml 100ml 100ml 100ml 100ml 100ml 
 
Determination of UV Absorbance Maxima of 
Ranitidine Hydrochloride- The standard stock solution 
was used to determination the λ max of (0.1 N HCl, pH 
1.2) was used as blank for the study. The spectrum was 
taken between the UV range of 200-400nm. The highest 
peak obtained from the spectrum analysis was taken as λ 
max for Ranitidine Hydrochloride. 
Preparation of standard calibration curve of Ranitidine 
Hydrochloride- Ranitidine Hydrochloride (10 mg) was 
dissolved in (0.1 N HCl, pH 1.2) and volume was made up 
to 100 ml in 100 ml volumetric flask. This solution (100 
mcg/ml) was further diluted with (0.1 N HCl, pH 1.2) to 
obtain solution of 10 to 100 mcg/ml. The absorbance of 
each solution was measured at 314 nm using UV 
spectrophotometer. The standard curve was obtained by 
plotting absorbance v/s. concentration (g/ml) 3. 
Identification of Drug by FTIR- Compatibility of the 
ranitidine hydrochloride with gelling agent and other 
excipients was established by infrared spectral analysis IR 
Spectral analysis of samples (Ranitidine hydrochloride, 
Sodium Citrate, Sodium alginate, calcium carbonate, 
sorbitol) was carried out to investigate the changes in 
chemical composition of the drug4. 
Physical Appearance and pH:- All the prepare sodium 
alginate based in situ solution were checked for their 
clarity and the type of the solution. After administration of 
the prepared solution in (0.1N HCL, pH 1.2) also checked 
the time required for gel formation and type of gel formed. 
The pH was measured in each of the solution of sodium 
alginate based in situ solution using a calibrated digital pH 
meter at 270C. the measurement of pH of each data were in 
triplicate5. 
Viscosity of in situ gelling solutions – The viscosity of 
formulations was determined by a Brookfield viscometer 
DV-III (Brookfield, USA) using spindle number 21 with 
cup and bob setting at 50 rpm6. 
Floating behaviour – The floating ability of the prepared 
formulations was evaluated in (0.1N HCl, pH 1.2) 
Solution. The floating time of the prepared formulation 
took to emerge on the medium surface (floating lag time) 
was found to be 60sec.The time the formulation constantly 
floated on the dissolution medium surface (duration of 
floating) was evaluated to be 12hrs resulting the formation 
of thick gel with good floating tendency7.  
In-vitro gelling capacity - To evaluate the formulations 
for their in-vitro gelling capacity by visual method, 
solutions of in situ gel forming drug delivery system were 
prepared. The in-vitro gelling capacity of prepare 
formulations was measured by placing 5 ml of the gelation 
solution (0.1N HCL, pH 1.2) in a 15 ml borosilicate glass 
test tube and maintained at 37±1ºC temperature. One ml of 
formulation solution was added with the help of pipette. 
The formulation was transferred in such a way that places 
the pipette at surface of fluid in test tube and formulation 
was slowly released from the pipette. As the solution 
comes in contact with gelation solution, it was 
immediately converted into stiff gel like structure. The 
gelling capacity of solution was evaluated on the basis of 
stiffness of formed gel and time period for which the 
formed gel remains as such. The in-vitro gelling capacity 
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was graded in three categories on the basis of gelation time 
and time period for which the formed gel remains. 
(+) Gels after few minutes, dispersed rapidly 
(++) Gelation immediate remains for 12 hours 
(+++) Gelation immediate remains for more than 12 
hours8. 
Drug content: 
Ten ml of the solution was added to 900 ml (0.1N HCl, pH 
1.2) Solution and stirred for 1 hr. on a magnetic stirrer. 
The solution was filtered, suitably diluted with (0.1N HCl, 
pH 1.2) and the drug concentration was determined by 
using a UV-visible spectrophotometer a (Shimandzu UV 
1700 Pharmaspec) at 314 nm against a suitable blank 
solution2. 
In vitro release studies: 
An in vitro release study was carried out using dissolution 
test apparatus USP Type II (Paddle Method). The 
following procedure was followed throughout the study 
that is shown in (table 2) to determine the in vitro 
dissolution rate for the formulations. The release of 
ranitidine from the formulations was determined using 
dissolution test apparatus USP Type II with a paddle stirrer 
at 50 rpm. The dissolution medium used 900 ml of (0.1N 
HCL, pH 1.2) solution and temperature was maintained at 
37 ± 0.2 °C. Ten ml of the formulation were placed into a 
Petri dish (4.5 cm i.d.) which was kept in the dissolution 
vessel and 0.1N HCL solution was carefully added to the 
vessel avoiding any disturbance of the Petri dish. At each 
time interval, a precisely measured sample of the 
dissolution medium was pipetted out and replenished with 
fresh medium. Ranitidine hydrochloride concentration in 
the aliquot was determined spectrophotometrically9. 
Table: 2 Dissolution of Floating In Situ Gel 
Dissolution 
medium 
900 ml of (0.1N HCL,1.2 pH) 
solution 
Temperature 37 0C0.2 0C 
RPM 50 
Volume withdrawn 10 ml every 1 hrs. 
max 314 nm 
Sol. taken Ten ml sol. (Known drug content ) 
 
Drug release kinetic studies: 
The drug release kinetic studies were done by various 
mathematical models (zero order, first order, Higuchi’s 
square root, Hixson-Crowell cube root law and Pappas 
equation). The model that best fits the release data is 
selected based on the correlation coefficient (r) value in 
various models. The model that gives high ‘r’ value is 
considered as the best fit of the release data. The release 
constant was calculated from the slope of the appropriate 
plots, and the regression coefficient (r2) was determined10. 
Stability testing:  
preparation of sodium alginate based in situ gel of 
Ranitidine hydrochloride was stored in glass 
container(well stoppered) for 1, 2 & 3 month and the 
stability of the aqueous solution of the sodium alginate 
based in situ gel of Ranitidine hydrochloride was 
monitored up to three month at accelerated stability 
condition (45ºC temp. And 75% RH) periodically sample 
were removed and characterized by pH, viscosity and drug 
content11. 
RESULT AND DISCUSSION 
Determination of UV Absorbance Maxima of 
Ranitidine Hydrochloride- The standard stock solution 
was used to determination the λ max of (0.1 N HCl, pH 
1.2) was used as blank for the study. The spectrum was 
taken between the UV range of 200-400nm. The highest 
peak obtained from the spectrum analysis was taken as λ 
max for Ranitidine Hydrochloride that used was found to 
be 314 nm. 
Figure 1: Standard Calibration Curve of Ranitidine HCl 
 
 
Identification of Drug by FTIR 
Identification study was performed using FTIR 
spectrophotometer. The characteristic absorption peaks of 
Ranitidine hydrochloride were obtained at different wave 
numbers. The peaks obtained in the spectra of pure drug 
correlates with the peaks of official spectrum of British 
Pharmacopeia which confirms the purity of drug.
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Figure 2 IR spectra of Ranitidine hydrochloride 
 
 
Figure 3 IR spectra of Ranitidine hydrochloride with sodium alginate 
 
 
Figure 4: IR spectra of Ranitidine hydrochloride+ sodium citrate 
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Figure 5: IR spectra of Ranitidine hydrochloride with Excipients 
 
 
Figure 6: IR spectra of Ranitidine hydrochloride+ calcium carbonate 
 
Physical Appearance and pH 
All the prepared sodium alginate based in situ solution of 
Ranitidine hydrochloride were checked for their clarity and 
the type of the solution. After administration of the 
prepared  solution in (0.1N HCL, ph 1.2) also checked the 
time required for gel formation and type of gel formed. 
The pH was measured in each of the solution of sodium 
alginate based in situ solution of Ranitidine hydrochloride, 
using a calibrated digital pH meter. The measurement of 
pH of data were in triplicate and the Average values given 
in Table 3 
 
 
Table 3: pH of prepared In situ gel formulation 
 
 
 
 
Viscosity  
The viscosity of the formulations increased with an 
increase in sodium alginate concentration. This 
phenomenon is a consequence of increasing chain 
interaction with an increase in polymer concentration. 
Calcium carbonate, which is  the source of cations, 
increased the viscosity of the formulation. This change in 
viscosity is due to the proportional increase in the amount 
of dispersed calcium carbonate. 
 
Formulation code F1 F2 F3 F4 F5 F6 
pH 7.4 7.4 7.1 7.1 6.9 7.0 
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Table 4: Viscosity of prepared In situ gel formulation 
 
 
 
 
Floating Behaviour 
The buoyancy lag time varied with the formulation 
variables. Formulation F6 exhibited the least buoyancy lag 
time (41 s) while formulation F2 exhibited the highest lag 
time (59 s). The decrease in the buoyancy lag time of a 
formulation F6 can be attributed to the availability of an 
increased the concentration of calcium carbonate was 
increased, being entrapped in the formed gel to give rapid 
buoyancy. Irrespective of formulation variables, buoyancy 
duration was > 12 hours. 
 
Table 5: Floating behaviour of prepared In situ gel formulation 
 
 
 
 
Figure 7: Floating behaviour of In situ gel formulation 
 
 
Gelling Capacity  
In vitro gelling capacity of various formulation of in situ floating gel is reported in table  
 
Figure 8: Gelling capacity of in situ floating gel formulation 
                      Table 6: Gelling capacity of prepared In situ gel formulation 
 
 
 
Drug Content 
The Drug content of all (F1-F6) formulations is given in table no 7, It ranges in between 97.08% - 98.62%. The values are 
acceptable as per united state pharmacopeia standards. 
Formulation code F1 F2 F3 F4 F5 F6 
Viscosity(cp) 97 132 154 191 234 264 
Formulation code F1 F2 F3 F4 F5 F6 
Floating lag time(sec) 50 59 50 40 43 41 
Floating time(hr) >12 >12 >12 >12 >12 >12 
Formulation code F1 F2 F3 F4 F5 F6 
Gelling capacity ++ ++ ++ +++ +++ +++ 
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Table 7: Results of Drug Content of all formulation of Ranitidine HCL 
Formulation code F1 F2 F3 F4 F5 F6 
Content uniformity 
(%)* 
98.03 
±0.38 
98.09 
±0.38 
98.54 
±0.40 
97.08 
±0.40 
98.03 
±0.42 
98.62 
±0.42 
 
In-Vitro Drug Release:  
The in-vitro drug releases of the in situ floating gel were 
carried in (0.1N HCl, 1.2 pH) solution from 0 to 8 hrs by 
using dissolution test apparatus USP Type II (Paddle 
Method). The samples were withdrawn at different time 
intervals and analyzed at 314 nm. Percentage Cumulative 
drug release was calculated on the basis of mean amount 
of Ranitidine hydrochloride present in the respective 
solution. The results obtained in the in vitro drug release 
for the formulations F1 to F6 in (Table 8). The plots are 
shown in (Figure no. 5) for % cumulative drug release VS 
time. Formulation F1, F2, F3, F4, F5 and F6 released 
about 93.01 %, 90.03 %, 89.60%, 79.58%, 72.59% ,70.16 
of drug after 8 hrs. Respectively. The results are shown in 
figure 5 indicate that the formulation, F6  which was 
prepared by the Sodium alginate (2%) with Ranitidine 
showed minimum drug release after 8 hrs. Thus, the 
formulation (F6) has better result as comparison to others 
formulations as sustained release. 
 
Table 8: In-Vitro Drug release of Ranitidine HCL in situ gel Formulations (F1- F6) 
Time (Hrs.) 
% cumulative drug release from various batches  
F1 F2 F3 F4 F5   F6 
0 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
1 15.10 23.04 8.09 28.63 21.56 25.45 
2 18.03 29.00 21.05 39.00 28.53 33.76 
3 45.06 46.76 23.43 42.64 39.46 38.76 
4 59.76 62.02 33.45 48.76 44.76 46.56 
5 73.56 76.78 38.54 52.56 48.67 50.76 
6 86.75 79.65 44.65 57.98 53.56 55.98 
7 89.87 88.91 76.54 62.15 68.35 62.64 
8 90.03 93.01 89.60 72.59 79.58 70.16 
                                  
Figure 9: In-vitro Release Profile of Ranitidine HCL (F1 To F6) 
 
Drug Release Kinetics Studies: 
The drug release data of Ranitidine were fitted to models 
representing Higuchi’s, zero order, first order, Hixson-
crowell and Korsmeyer’s equation kinetics to know the 
release mechanisms. The data were processed for 
regression analysis using Ms Excel statistical function. The 
results are shown in (Table 9). 
It was found that the in vitro drug release of optimize batch 
F6 was best explained by zero order as the plots showed 
the highest linearity (R2 = 0.9954). The formulation code 
F6 followed the zero order. 
Table 9: Kinetic Models Studies of F6 batch. 
Formulation 
code 
Zero order First order Higuchi 
R
2
 R
2
 R
2
 
F6 0.995 0.952 0.980 
Stability Studies: 
Stability studies carried out at 40 ± 2oC/ 75 ± 5 % RH and 
at room temperature for 90 days showed no significant 
change in the content of Ranitidine hydrochloride. Typical 
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properties of the significant change in physical appearance, 
viscosity, drug content, in vitro drug release and Floating 
behaviour to stability studies. 
 
Table 10: stability Studies of F6 Batch. 
 
 
 
Figure 10: Comparison of % drug release before and 
after stability 
 
SUMMARY & CONCLUSION: 
The present investigation dealt with the formulation, 
optimization and evaluation of sodium alginate based in 
situ gel of ranitidine hydrochloride. Sodium alginate and 
calcium carbonate used as a polymer and cross-linking 
agent respectively. The in situ formulations were exhibited 
well, viscosity, drug content and sustained drug release. 
This study reports that oral administration of aqueous 
solution containing sodium alginate result in formation of 
in situ gel. Such formulation are homogenous liquid when 
administration orally and become gel at the contact site. 
The evaluation of the formulation is dependent upon 
accurate results obtained by analytical method used during 
the study. Accurate results require the use of standard and 
a calibration procedure. Hence, standard plots of 
Ranitidine hydrochloride were prepared in (0.1N HCL, pH 
1.2) solutions. Ranitidine hydrochloride was analyzed 
using UV spectrophotometer. Two different were sodium 
alginate and calcium carbonate used as a polymer and 
cross-linking agent respectively in the formulation of in 
situ gel. Among different excipients used, sodium citrate, 
sorbitol etc.  From the IR studies it may be concluded that 
the drug and carriers used undergo physical interaction 
there is no chemical change, and thus the gelling agent, 
cross-linking agent and other excipients are suitable for 
formulation of in situ gel of ranitidine hydrochloride. 
Formulation F1, F2, F3, F4, F5 and F6 released about 
90.03 %, 93.01 %, 89.60 %, 72.59%, 79.58% and 70.16 %  
of drug after 8 hrs respectively. Indicate that the 
formulation, F6 which was prepared by the Sodium 
alginate (2 gm) with Ranitidine Hydrochloride showed 
minimum drug release (sustained drug release) after 8 hrs. 
Thus, the formulation (F6) has better result as comparison 
to others formulations. The optimized formulation was 
found to be stable at room temperature for 90 days showed 
no significant change in the content of Ranitidine 
hydrochloride. no significant change was observed in the 
content uniformity, Viscosity and drug release of the In 
situ gel. All other parameters were also observed to be 
comparable. It could be concluded from study that 
optimized formulation was stable at room temperature.
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                 Stability study for pectin based in situ formulation batch F6 
Time period for sampling pH Viscosity (cp) Drug content (%) Drug release (%) 
Initial 7.0 264 98.62 70.16 
After 1 month 7.0 264 98.60 69.56 
After 2 month 7.03 268 98.55 70.16 
After 3 month 7.09 268 98.00 70.16 
